| Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance AP Magiorakos, A Srinivasan, RB Carey, Y Carmeli, ME Falagas, ... Clinical microbiology and infection 18 (3), 268-281, 2012 | 14839 | 2012 |
| Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis E Tacconelli, E Carrara, A Savoldi, S Harbarth, M Mendelson, DL Monnet, ... The Lancet infectious diseases 18 (3), 318-327, 2018 | 6051 | 2018 |
| Comparison of Mortality Associated with Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Meta-analysis SE Cosgrove, G Sakoulas, EN Perencevich, MJ Schwaber, AW Karchmer, ... Clinical infectious diseases 36 (1), 53-59, 2003 | 2725 | 2003 |
| The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges SE Cosgrove, Y Qi, KS Kaye, S Harbarth, AW Karchmer, Y Carmeli Infection Control & Hospital Epidemiology 26 (2), 166-174, 2005 | 1284 | 2005 |
| Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients with Staphylococcus aureus Surgical Site Infection JJ Engemann, Y Carmeli, SE Cosgrove, VG Fowler, MZ Bronstein, ... Clinical infectious diseases 36 (5), 592-598, 2003 | 1268 | 2003 |
| Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe R Cantón, M Akóva, Y Carmeli, CG Giske, Y Glupczynski, M Gniadkowski, ... Clinical microbiology and infection 18 (5), 413-431, 2012 | 1154 | 2012 |
| Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact V Aloush, S Navon-Venezia, Y Seigman-Igra, S Cabili, Y Carmeli Antimicrobial agents and chemotherapy 50 (1), 43-48, 2006 | 1129 | 2006 |
| The negative impact of antibiotic resistance ND Friedman, E Temkin, Y Carmeli Clinical microbiology and infection 22 (5), 416-422, 2016 | 975 | 2016 |
| Clinical and economic impact of common multidrug-resistant gram-negative bacilli CG Giske, DL Monnet, O Cars, Y Carmeli Antimicrobial agents and chemotherapy 52 (3), 813-821, 2008 | 930 | 2008 |
| The impact of antimicrobial resistance on health and economic outcomes GM Eliopoulos, SE Cosgrove, Y Carmeli Clinical infectious diseases 36 (11), 1433-1437, 2003 | 873 | 2003 |
| Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis MJ Schwaber, Y Carmeli Journal of Antimicrobial Chemotherapy 60 (5), 913-920, 2007 | 870 | 2007 |
| Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance S Harbarth, MH Samore, D Lichtenberg, Y Carmeli Circulation 101 (25), 2916-2921, 2000 | 857 | 2000 |
| Emergence of Antibiotic-Resistant Pseudomonas aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents Y Carmeli, N Troillet, GM Eliopoulos, MH Samore Antimicrobial agents and chemotherapy 43 (6), 1379-1382, 1999 | 854 | 1999 |
| Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality MJ Schwaber, S Klarfeld-Lidji, S Navon-Venezia, D Schwartz, A Leavitt, ... Antimicrobial agents and chemotherapy 52 (3), 1028-1033, 2008 | 691 | 2008 |
| Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective … H Grundmann, C Glasner, B Albiger, DM Aanensen, CT Tomlinson, ... The Lancet infectious diseases 17 (2), 153-163, 2017 | 690 | 2017 |
| Molecular Epidemiology of KPC-Producing Klebsiella pneumoniae Isolates in the United States: Clonal Expansion of Multilocus Sequence Type 258 B Kitchel, JK Rasheed, JB Patel, A Srinivasan, S Navon-Venezia, ... Antimicrobial agents and chemotherapy 53 (8), 3365-3370, 2009 | 681 | 2009 |
| A Multinational Survey of Risk Factors for Infection with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Nonhospitalized Patients R Ben-Ami, J Rodríguez-Baño, H Arslan, JDD Pitout, C Quentin, ES Calbo, ... Clinical Infectious Diseases 49 (5), 682-690, 2009 | 678 | 2009 |
| Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae MJ Schwaber, S Navon-Venezia, KS Kaye, R Ben-Ami, D Schwartz, ... Antimicrobial agents and chemotherapy 50 (4), 1257-1262, 2006 | 603 | 2006 |
| Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial M Paul, GL Daikos, E Durante-Mangoni, D Yahav, Y Carmeli, YD Benattar, ... The lancet Infectious diseases 18 (4), 391-400, 2018 | 587 | 2018 |
| Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective … B Gutiérrez-Gutiérrez, E Salamanca, M de Cueto, PR Hsueh, P Viale, ... The Lancet Infectious Diseases 17 (7), 726-734, 2017 | 525 | 2017 |
Shiri Navon-VeneziaProfessor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab, Ariel Universityبريد إلكتروني تم التحقق منه على ariel.ac.il
